DexCom Inc (DXCM)vsIRIDEX Corporation (IRIX)
DXCM
DexCom Inc
$75.14
+0.39%
HEALTHCARE · Cap: $29.58B
IRIX
IRIDEX Corporation
$0.86
-1.95%
HEALTHCARE · Cap: $15.51M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 9063% more annual revenue ($4.82B vs $52.58M). DXCM leads profitability with a 19.3% profit margin vs -6.2%. IRIX appears more attractively valued with a PEG of 0.94. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
IRIX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.6%
Fair Value
$656.95
Current Price
$75.14
$581.81 discount
Margin of Safety
+75.3%
Fair Value
$5.79
Current Price
$0.86
$4.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DXCM profiles as a mature stock while IRIX is a turnaround play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 32/100), backed by strong 19.3% margins and 15.0% revenue growth. IRIX offers better value entry with a 75.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?